the aid library

LIST OPTIONS

Filter

7328

The ASSIST-linked brief intervention for hazardous and harmful substance use

World Health Organization WHO (2010) C_WHO

Manual for use in primary care. This manual explains the theoretical basis and evidence for the effectiveness of brief interventions and assists primary health care workers in conducting a simple b... more

Download (134)

View PDF (159)

MHPSS COVID-19 Toolkit Version 1.0 Coronavirus Disease (COVID-19) Pandemic

Mental Health and Psychosocial Support Network MHPSS.net (2020) CC

The COVID-19 pandemic is a rapidly evolving global crisis and there is much that is still emerging in terms of the psychosocial and mental health consequences for the diverse populations affected ... more

Download (137)

View PDF (162)

Practical Guidance for Risk Communication and Community Engagement (RCCE) for Refugees, Internally Displaced Persons (IDPs), Migrants, and Host Communities Particularly Vulnerable to COVID-19 Pandemic
recommended

International Federation of Red Cross and Red Crescent Societies IFRC (2020) CC

This practical guidance is designed to assist programme specialists to implement COVID19 RCCE activities for and with refugees, IDPs, migrants and host communities vulnerable to the pandemic. The guidance highlights key challenges and barriers faced by these people in accessing COVID19 ...-related information and presents key considerations and recommendations for planning and implementing RCCE activities. The document can be adapted to countries’ specific context and aligned with national response plans for COVID-19 and national RCCE plans. more

Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV
recommended

World Health Organization WHO (2020) C_WHO

Histoplasmosis is a disease caused by the fungus Histoplasma capsulatum. This disease is highly endemic in some regions of North America, Central America, and South America and is also reported in certain countries ... Asia and Africa. It often affects people with impaired immunity, including people living with HIV, among whom the most frequent clinical presentation is disseminated histoplasmosis. The symptoms of disseminated histoplasmosis are non-specific and may be indistinguishable from those of other infectious diseases, especially disseminated tuberculosis (TB), thus complicating diagnosis and treatment. Histoplasmosis is one of the most frequent opportunistic infections caused by fungal pathogens among people living with HIV in the Americas and may be responsible for 5–15% of AIDS-related deaths every year in this Region. These guidelines aim to provide recommendations for the diagnosis, treatment, and management of disseminated histoplasmosis in persons living with HIV more

Download (77)

View PDF (109)

Global Adult Tobacco Survey: Executive Summary 2016

World Health Organization WHO (2016) C_WHO

Ethiopia GATS was implemented by Ethiopia Public Health Institute (EPHI) in collaboration with the Ethiopian Food, Medicine, Health Care Administration and Control Auth... more

Portable digital radiography system: technical specifications

World Health Organization WHO (2021) C_WHO

The portable diagnostic imaging technology covered by this document will serve not only the pressing demands for tuberculosis screening and triage but also other diseases. Therefore, the requirements, accessories, hardware and software packages listed in the following specifications are described in... more

Download (181)

View PDF (228)

Global tuberculosis report 2022
recommended

World Health Organization WHO (2022) C_WHO

The WHO Global Tuberculosis Report 2022 provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment ... the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets. The 2022 edition of the report is as usual, based primarily on data gathered by WHO from national ministries of health in annual rounds of data collection. In 2022, 202 countries and territories with more than 99% of the world’s population and TB cases reported data more

Five keys for safer traditional food markets: risk mitigation in traditional food markets in the Asia-Pacific Region

World Health Organisation (WHO) (2023) C_WHO

Traditional food markets play important economic, cultural, and social role and are sources of livelihood for millions of people in urban and rural areas. The manual Five keys for safer traditional ... more

Download (181)

View PDF (165)

WHO report on the global tobacco epidemic, 2023: protect people from tobacco smoke

World Health Organisation (WHO) (2023) C_WHO

The ninth WHO report on the global tobacco epidemic tracks the progress made by countries in tobacco control since 2008 and, marks 15 years since the introduction of the MPOWER technical package which is designed to help countries implement the dema... more

From emergency response to long-term COVID-19 disease management - Ending the COVID-19 emergency and transitioning from emergency phase to longer-term disease management: Guidance on calibrating the r

World Health Organization WHO (2023) C_WHO

The key actions, activities, and approaches in this document are organized within each of the 5Cs (see Table 1 in the PDF) and those of the Strategic preparedness and response plan (SPRP) pillars as... more

WHO competency framework, risk communication and community engagement

World Health Organization WHO (2024) C_WHO

The risk communication and community engagement (RCCE) competency framework is a resource that details the essential behaviours and activities necessary for effective communication and engagement with communities before, during and after public health... more

Sanitation inspections User guide

World Health Organization WHO (2024) C_WHO

Safe sanitation is essential for health, from preventing infections to improving and maintaining mental and social well-being. Lack of adequate sanitation contributes to diarrhoeal diseases, parasi... more

Laboratory Biorisk Management: Strategic Framework for Action 2012–2016

World Health Organization WHO (2012)

This document presents a strategic framework, aimed towards the development of sustainable global, regional and national plans relating to laboratory biorisk management.

Download (290)

View PDF (385)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Antimicrobial resistance and the United Nations sustainable development cooperation framework: guidance for United Nations country teams

World Health Organisation (WHO) (2021) C_WHO

World Health Organization, Food and Agriculture Organization of the United Nations & World Organisation for Animal Health. (‎2021)‎. Antimicrob... more

Download (462)

View PDF (734)

Vision impairment and blindness - Fact Sheet

World Health Organization (WHO) (2017) C_WHO

An estimated 253 million people live with vision impairment: 36 million are blind and 217 million have moderate to severe vision impairment. 81% of people who are blind or have moderate or severe vision impairment are aged 50 years and above

Download (524)

View PDF (518)

Eliminate Yellow fever Epidemics (EYE): a global strategy, 2017-2026

World Health Organization WHO (2018) C_WHO

The EYE strategy is a comprehensive and long-term strategy built on lessons learned that aims at ending yellow fever epidemics by 2026, and consists of three strategic objectives: protect at-risk populations; prevent international spread; ... more

WHO good manufacturing practices for pharmaceutical products: main principles

World Health Organization WHO (2014) C_WHO

Licensed pharmaceutical products (marketing authorization) should be manufactured only by licensed manufacturers (holders of a manufacturing authorization) whose activities are regularly inspected by competent national authorities. This guide to GMP... more

Download (564)

View PDF (579)

Water Safety Plans - Training package. Participant workbook

World Health Organization (WHO), International Water Association (IWA) (2012) C_WHO

The workshop is structured around 13 learning modules. The first module (Introduction) gives an overview of WSPs. The last module (Module 12) introduces participants to the quality assurance tool for WSPs (WHO & IWA, 2012). Modules 1–11 relate exp... more

External Link

The Practical Approach to Care Kit (PACK) Nigeria

Knowledge Translation Unit, BMJ and Health Resources International West Africa (HRIWA) (2021) CC

PACK Nigeria (Adult and Child) provides a single, integrated, comprehensive, evidence-informed clinical guide to support all cadres working in primary healthcare in Nigeria: i.e. junior community health extension workers (JCHEWs), community ... extension workers (CHEWs), community health officers (CHOs), nurses, midwives and medical officers. Colour-coding is used to clearly delineate the scope of practice of these different cadres and clarify referral pathways. This integration promotes a team-based approach to a patient’s care and enables patients to receive consistent and standardized care from whichever cadre treats them. You can register for free and get the PACK Global Adult Guide for free more

Practical Guidance for Risk Communication and Community Engagement (RCCE) for Refugees, Internally Displaced Persons (IDPs), Migrants, and Host Communities Particularly Vulnerable to COVID-19 Pandemic recommended

Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV recommended

Global tuberculosis report 2022 recommended

Practical Guidance for Risk Communication and Community Engagement (RCCE) for Refugees, Internally Displaced Persons (IDPs), Migrants, and Host Communities Particularly Vulnerable to COVID-19 Pandemic
recommended

Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV
recommended

Global tuberculosis report 2022
recommended